


Expanding Our Mission to Immuno-oncology

*MORE choice
without
compromise*



Building on our success with UDENYCA[®] (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences' novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

About Coherus
Immuno-oncology

Toripalimab at
ASCO 2021

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences' anti-PD-1 antibody.

[> Learn More](#)

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

[> Learn More](#)

Latest News

Biosciences' anti-PD-1 antibody.

[> Learn More](#)

generated by our commercial biosimilar business.

[> Learn More](#)

Latest News

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

[Learn More](#)

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

[Learn More](#)

Coherus BioSciences Announces New Employment Inducement Grants

[Learn More](#)

Coherus issues white paper supporting “Securing America’s Medicines & Supply”

[View Now](#)

> About Coherus

Leadership Team

Board of Directors

Scientific Advisory Board

Commercial Advisory Committee

Contact Us

> Immuno-oncology

Toripalimab Program

> Biosimilars

Unique Development Process

FDA Approval Process

> Products and Pipeline

UDENYCA® (pegfilgrastim-cbqv)

Coherus COMPLETE™

Medical Information

> Investors

> Join Our Team

Openings

> Privacy Policy

> Contact Us



Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website.



[Privacy Policy](#) [Site Map](#) [Contact Us](#) [Join Our Team](#)

Copyright © 2021 Coherus BioSciences 0617-UDY-P015

Welcome to Coherus COMPLETE™

Shattering the standards of patient access support



I am a Patient

I am a
Healthcare
Practitioner



> Coding & Reimbursement

> Payer Coverage

> Financial Assistance

> Biosimilar Value

> Support Resources

> Privacy Policy

Contact Us

1-844-4-UDENYCA

(1-844-483-3692)

Fax 1-877-226-6370

Coherus.com | UDENYCA.com

PRODUCTS & Pipeline



PRODUCTS AND PIPELINE

UDENYCA® (pegfilgrastim-cbqv)

Coherus COMPLETE™

Medical Information

At Coherus, we put patients first.

WE ARE DEDICATED TO IMPROVING THE AVAILABILITY OF HIGH-VALUE, HIGH-QUALITY THERAPEUTICS. OUR PIPELINE SPANS MULTIPLE THERAPEUTIC AREAS INCLUDING ONCOLOGY, IMMUNOLOGY, AND OPHTHALMOLOGY.

Our first product, UDENYCA® (pegfilgrastim-cbqv), is an FDA-approved pegfilgrastim biosimilar.

With our expansion into immuno-oncology, toripalimab clinical trial results are expected over the next several years from a broad registrational clinical development program across multiple tumor types including cancers of the lung, esophagus, bladder, nasopharynx, stomach, breast, liver, and skin.

Our strategy is to invest cash flows from our commercial biosimilar business to build a fast-follower immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.

TORIPALIMAB†, PD-1 INHIBITOR

Organ Group	Proposed Indication	Dose Escalation / Expansion (Phase 1 / 2)	Pivotal Clinical Trials	BLA Submission	Approved / Marketed*
Head and Neck	Nasopharyngeal carcinoma (3L, mono)	██████████	██████████	██████████	
	Nasopharyngeal carcinoma (1L, combo with chemo)	██████████	██████████		
Lung	NSCLC (1L, combo with chemo)	██████████	██████████		
	EGFR mutated TKI failed NSCLC (combo with chemo)	██████████	██████████		
	NSCLC (neoadjuvant)	██████████	██████████		
	SCLC (1L, combo with chemo)	██████████	██████████		
Breast	TNBC (combo with albumin-bound paclitaxel)	██████████	██████████		
Gastrointestinal	ESCC (1L, combo with chemo)	██████████	██████████		
	ESCC (neoadjuvant)	██████████	██████████		
	HCC (1L, combo with lenvatinib)	██████████	██████████		
	HCC (1L, combo with bevacizumab)	██████████	██████████		
	HCC (adjuvant)	██████████	██████████		
	Gastric carcinoma (3L, mono)	██████████	██████████		

Gastrointestinal	ESCC (1L, combo with chemo)		
	ESCC (neoadjuvant)		
	HCC (1L, combo with lenvatinib)		
	HCC (1L, combo with bevacizumab)		
	HCC (adjuvant)		
Genitourinary	Gastric carcinoma (3L, mono)		
	Urothelial carcinoma (2L, mono)		
	Urothelial carcinoma (1L, PD-L1+)		
Skin	Renal cell carcinoma (1L, combo with axitinib)		
	Melanoma (2L, mono)		
	Melanoma (1L, mono)		
Multiple	Mucosal melanoma (combo with axitinib)		
	Soft Tissue Sarcoma		

BIOSIMILARS

Therapeutic Area	Product / Originator	Pre-clinical / Early Clinical	Pivotal Clinical Trials	BLA Submission	Approved / Marketed*
Oncology	UDENYCA® (pegfilgrastim-cbqv)				
	CHS-305 (bevacizumab biosimilar) [†]				
Ophthalmology	CHS-201 (ranibizumab biosimilar) [‡]				
Immunology	CHS-1420 (adalimumab biosimilar) [§]				

* In the United States
[†] Licensed from Junshi
[‡] Licensed from Innovent
[§] Licensed from Bioeq

> About Coherus

- Leadership Team
- Board of Directors
- Scientific Advisory Board
- Commercial Advisory Committee
- Contact Us

> Immuno-oncology

- Toripalimab Program

> Biosimilars

- Unique Development Process
- FDA Approval Process

> Products and Pipeline

- UDENYCA® (pegfilgrastim-cbqv)
- Coherus COMPLETE™
- Medical Information

> Investors

- > Join Our Team
- Openings

> Privacy Policy

> Contact Us



Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website.

Gastrointestinal	HCC (1L, combo with lenvatinib)	
	HCC (1L, combo with bevacizumab)	
	HCC (adjuvant)	
	Gastric carcinoma (3L, mono)	
Genitourinary	Urothelial carcinoma (2L, mono)	
	Urothelial carcinoma (1L, PD-L1+)	
	Renal cell carcinoma (1L, combo with axitinib)	
Skin	Melanoma (2L, mono)	
	Melanoma (1L, mono)	
	Mucosal melanoma (combo with axitinib)	
Multiple	Soft Tissue Sarcoma	

BIOSIMILARS					
Therapeutic Area	Product / Originator	Pre-clinical / Early Clinical	Pivotal Clinical Trials	BLA Submission	Approved / Marketed*
Oncology	UDENYCA® (pegfilgrastim-cbqv)				
	CHS-305 (bevacizumab biosimilar) [†]				
Ophthalmology	CHS-201 (ranibizumab biosimilar) [‡]				
Immunology	CHS-1420 (adalimumab biosimilar) [§]				

* In the United States

[†] Licensed from Junshi

[‡] Licensed from Innovent

[§] Licensed from Bioeq

> About Coherus

Leadership Team

Board of Directors

Scientific Advisory Board

Commercial Advisory Committee

Contact Us

> Immuno-oncology

Toripalimab Program

> Biosimilars

Unique Development Process

FDA Approval Process

> Products and Pipeline

UDENYCA® (pegfilgrastim-cbqv)

Coherus COMPLETE™

Medical Information

> Investors

> Join Our Team

Openings

> Privacy Policy

> Contact Us



Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website.




[Privacy Policy](#) [Site Map](#) [Contact Us](#) [Join Our Team](#)

Copyright © 2021 Coherus BioSciences

Expanding Our Mission to Immuno-oncology

*MORE choice
without
compromise*



Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences' novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

About Coherus
Immuno-oncology

Toripalimab at
ASCO 2021

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences' anti-PD-1 antibody.

[> Learn More](#)

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

[> Learn More](#)

Latest News

Biosciences' anti-PD-1 antibody.

[> Learn More](#)

generated by our commercial biosimilar business.

[> Learn More](#)

Latest News

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

[Learn More](#)

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

[Learn More](#)

Coherus BioSciences Announces New Employment Inducement Grants

[Learn More](#)

Coherus issues white paper supporting “Securing America’s Medicines & Supply”

[View Now](#)

> About Coherus

Leadership Team

Board of Directors

Scientific Advisory Board

Commercial Advisory Committee

Contact Us

> Immuno-oncology

Toripalimab Program

> Biosimilars

Unique Development Process

FDA Approval Process

> Products and Pipeline

UDENYCA[®] (pegfilgrastim-cbqv)

Coherus COMPLETE[™]

Medical Information

> Investors

> Join Our Team

Openings

> Privacy Policy

> Contact Us



Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website.



[Privacy Policy](#) [Site Map](#) [Contact Us](#) [Join Our Team](#)

Copyright © 2021 Coherus BioSciences 0617-UDY-P015

Welcome to


Coherus COMPLETE™

Shattering the standards of patient access support



I am a Patient

I am a Healthcare Practitioner



> Coding & Reimbursement

> Payer Coverage

> Financial Assistance

> Biosimilar Value

> Support Resources

> Privacy Policy

Contact Us

1-844-4-UDENYCA

(1-844-483-3692)

Fax 1-877-226-6370

Coherus.com | UDENYCA.com

PRODUCTS & Pipeline



PRODUCTS AND PIPELINE

UDENYCA® (pegfilgrastim-cbqv)

Coherus COMPLETE™

Medical Information

At Coherus, we put patients first.

WE ARE DEDICATED TO IMPROVING THE AVAILABILITY OF HIGH-VALUE, HIGH-QUALITY THERAPEUTICS. OUR PIPELINE SPANS MULTIPLE THERAPEUTIC AREAS INCLUDING ONCOLOGY, IMMUNOLOGY, AND OPHTHALMOLOGY.

Our first product, UDENYCA® (pegfilgrastim-cbqv), is an FDA-approved pegfilgrastim biosimilar.

With our expansion into immuno-oncology, toripalimab clinical trial results are expected over the next several years from a broad registrational clinical development program across multiple tumor types including cancers of the lung, esophagus, bladder, nasopharynx, stomach, breast, liver, and skin.

Our strategy is to invest cash flows from our commercial biosimilar business to build a fast-follower immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.

TORIPALIMAB†, PD-1 INHIBITOR

Organ Group	Proposed Indication	Dose Escalation / Expansion (Phase 1 / 2)	Pivotal Clinical Trials	BLA Submission	Approved / Marketed*
Head and Neck	Nasopharyngeal carcinoma (3L, mono)	██████████	██████████	██████████	
	Nasopharyngeal carcinoma (1L, combo with chemo)	██████████	██████████		
Lung	NSCLC (1L, combo with chemo)	██████████	██████████		
	EGFR mutated TKI failed NSCLC (combo with chemo)	██████████	██████████		
	NSCLC (neoadjuvant)	██████████	██████████		
	SCLC (1L, combo with chemo)	██████████	██████████		
Breast	TNBC (combo with albumin-bound paclitaxel)	██████████	██████████		
Gastrointestinal	ESCC (1L, combo with chemo)	██████████	██████████		
	ESCC (neoadjuvant)	██████████	██████████		
	HCC (1L, combo with lenvatinib)	██████████	██████████		
	HCC (1L, combo with bevacizumab)	██████████	██████████		
	HCC (adjuvant)	██████████	██████████		
	Gastric carcinoma (3L, mono)	██████████	██████████		

Gastrointestinal	ESCC (1L, combo with chemo)		
	ESCC (neoadjuvant)		
	HCC (1L, combo with lenvatinib)		
	HCC (1L, combo with bevacizumab)		
	HCC (adjuvant)		
	Gastric carcinoma (3L, mono)		
Genitourinary	Urothelial carcinoma (2L, mono)		
	Urothelial carcinoma (1L, PD-L1+)		
	Renal cell carcinoma (1L, combo with axitinib)		
Skin	Melanoma (2L, mono)		
	Melanoma (1L, mono)		
	Mucosal melanoma (combo with axitinib)		
Multiple	Soft Tissue Sarcoma		

BIOSIMILARS

Therapeutic Area	Product / Originator	Pre-clinical / Early Clinical	Pivotal Clinical Trials	BLA Submission	Approved / Marketed*
Oncology	UDENYCA® (pegfilgrastim-cbqv)				
	CHS-305 (bevacizumab biosimilar) [†]				
Ophthalmology	CHS-201 (ranibizumab biosimilar) [‡]				
Immunology	CHS-1420 (adalimumab biosimilar) [§]				

* In the United States
[†] Licensed from Junshi
[‡] Licensed from Innovent
[§] Licensed from Bioeq

> **About Coherus**

- Leadership Team
- Board of Directors
- Scientific Advisory Board
- Commercial Advisory Committee
- Contact Us

> **Immuno-oncology**

- Toripalimab Program

> **Biosimilars**

- Unique Development Process
- FDA Approval Process

> **Products and Pipeline**

- UDENYCA® (pegfilgrastim-cbqv)
- Coherus COMPLETE™
- Medical Information

> **Investors**

> **Join Our Team**

- Openings

> **Privacy Policy**

> **Contact Us**

Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website.

Privacy Policy
Site Map
Contact Us
Join Our Team

Gastrointestinal	HCC (1L, combo with lenvatinib)	
	HCC (1L, combo with bevacizumab)	
	HCC (adjuvant)	
	Gastric carcinoma (3L, mono)	
Genitourinary	Urothelial carcinoma (2L, mono)	
	Urothelial carcinoma (1L, PD-L1+)	
	Renal cell carcinoma (1L, combo with axitinib)	
Skin	Melanoma (2L, mono)	
	Melanoma (1L, mono)	
	Mucosal melanoma (combo with axitinib)	
Multiple	Soft Tissue Sarcoma	

BIOSIMILARS					
Therapeutic Area	Product / Originator	Pre-clinical / Early Clinical	Pivotal Clinical Trials	BLA Submission	Approved / Marketed*
Oncology	UDENYCA® (pegfilgrastim-cbqv)				
	CHS-305 (bevacizumab biosimilar) [†]				
Ophthalmology	CHS-201 (ranibizumab biosimilar) [‡]				
Immunology	CHS-1420 (adalimumab biosimilar) [§]				

* In the United States

[†] Licensed from Junshi

[‡] Licensed from Innovent

[§] Licensed from Bioeq

> About Coherus

Leadership Team

Board of Directors

Scientific Advisory Board

Commercial Advisory Committee

Contact Us

> Immuno-oncology

Toripalimab Program

> Biosimilars

Unique Development Process

FDA Approval Process

> Products and Pipeline

UDENYCA® (pegfilgrastim-cbqv)

Coherus COMPLETE™

Medical Information

> Investors

> Join Our Team

Openings

> Privacy Policy

> Contact Us



Coherus uses cookies on this website. They help us to know a little bit about you and how you use our website.



[Privacy Policy](#) [Site Map](#) [Contact Us](#) [Join Our Team](#)

Copyright © 2021 Coherus BioSciences